Active Biotech AB (STU:BTP) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BTP Active Biotech AB STU:BTP
35 GF Score
Price €0.36
GF Value €0.13
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Active Biotech AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.00 Mil. Active Biotech AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.01 Mil. Active Biotech AB's annualized EBITDA for the quarter that ended in Jun. 2026 was €-3.56 Mil. Active Biotech AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Active Biotech AB's Debt-to-EBITDA or its related term are showing as below:

STU:BTP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.94   Med: -0.1   Max: -0.02
Current: -0.05

During the past 13 years, the highest Debt-to-EBITDA Ratio of Active Biotech AB was -0.02. The lowest was -6.94. And the median was -0.10.

STU:BTP's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs STU:BTP: -0.05

Active Biotech AB  (STU:BTP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Active Biotech AB Debt-to-EBITDA Related Terms


Active Biotech AB Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Active Biotech AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB Debt-to-EBITDA Chart

Active Biotech AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Active Biotech AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STU:BTP vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Active Biotech AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Active Biotech AB Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Active Biotech AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Active Biotech AB's Debt-to-EBITDA falls into.


STU:BTP
35GF Score
Active Biotech AB STU:BTP
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Active Biotech AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Active Biotech AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.14824024065733 + 0.01200699768564) / -3.2074695864292
=-0.05

Active Biotech AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.0090374820480756) / -3.563524476663
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Active Biotech AB (STU:BTP) Overvalued in 2026?

Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued. The current stock price of €0.36 is trading 179.2% above its estimated GF Value™ of €0.13. GuruFocus considers Active Biotech AB to be Significantly Overvalued.

Key valuation signals for STU:BTP:

  • Debt-to-EBITDA:
  • GF Value™: €0.13 vs. price of €0.36 (179.2% above fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the STU:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Active Biotech AB Business Description

Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
35GF Score

Get the complete analysis for STU:BTP

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.36
Price
€0.13
GF Value